Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA-PPQ + MQ vs DHA-PPQ or AS-MQ in Uncomplicated Falciparum Malaria in Cambodia
NCT02612545Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mefloquine in Malaria (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adequate Clinical and Parasitological Response at Day 42. Started Nov 2015; status: completed.
02
Drugs
mefloquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT02612545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612545.